Immutep S.a.s.
Clinical trials sponsored by Immutep S.a.s., explained in plain language.
-
Two-Drug immune attack shows promise against tough cancers
Disease control CompletedThis study tested a combination of two immune-boosting drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors safely. Participan…
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 17, 2026 01:46 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested whether adding an experimental drug (eftilagimod alpha) to a standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that cannot be removed by surgery. About 171 adults with PD-L1 positive or negative tumors took part. The goal was…
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC